Pharmaceuticals, Biotechnology & Life Sciences

Insight: Savitz Ryan’s April 2026 insider trades—buying at $17.88 and selling at $89.84—show a strategic confidence boost for Dianthus Therapeutics, blending long‑term stake with liquidity and market‑hedging, and hinting at potential upcoming corpor…

Goodman Noah’s 10b5‑1 plan buy at $21 boosts Kymera’s insider confidence, underscoring the company’s protein‑degradation potential and Gilead partnership.

Insider sales by eXoZymes’ CSO reveal routine portfolio moves amid a bullish 16% price surge and upcoming Nasdaq offering, showing confidence yet short‑term profit‑taking.

Insider confidence signals a potential upside for Chemomab Therapeutics, highlighting strategic pivot, clinical milestones and market sentiment to guide investors.

NovaBridge insider filing shows Xu Cong Claire keeps her stake steady amid market chatter—signifying confidence in the company’s biopharma pipeline.

Insider equity grants at Zymeworks signal executive confidence in its clinical‑stage growth and dual‑track strategy, hinting at a possible rally toward its 52‑week high.

Insightful analysis of Monte Rosa Therapeutics insider sales shows a subtle confidence shift, explaining recent stock trends and future outlook.

Insider buying spurs confidence in Immunovant, with executives buying over 140,000 shares amid market volatility, while tax‑cover sales show routine RSU management.

Insider confidence at Pfizer: Senior VP Dennis P. keeps a steady stake while others buy phantom stock, signaling long‑term optimism for the pharma giant.

Insider buying surge at Cue Biopharma signals confidence in a pre‑clinical milestone and partnership with Boehringer, hinting at future upside and volatility.